TARGETING HYPERMETHYLATION TO OVERCOME CISPLATIN RESISTANCE IN PATIENTS WITH RELAPSED/REFRACTORY GERM CELL TUMORS

$1,295,691FY2024Defense Health AgencyDOD

Sloan-Kettering Institute For Cancer Research

Investigators